+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

GR89,696 is a kappa-2 opioid receptor agonist and a kappa-1 opioid receptor antagonist in the guinea pig hippocampus

GR89,696 is a kappa-2 opioid receptor agonist and a kappa-1 opioid receptor antagonist in the guinea pig hippocampus

Journal of Pharmacology and Experimental Therapeutics 283(3): 1342-1349

Receptor binding studies and electrophysiological studies demonstrated the existence of at least two kappa opioid receptors, which have been designated kappa-1 and kappa-2. Several agonists and antagonists are selective for the kappa-1 receptor whereas no known ligands are selective for the kappa-2 receptor. In this study, the kappa opioid GR89,696 was tested in the guinea pig hippocampal slice preparation for kappa-1 versus kappa-2 activity. The perforant path-evoked population spike in the dentate was use to evaluate activity at the kappa-1 receptor, and the Schaffer collateral-evoked N-methyl-D-aspartate (NMDA) receptor-mediated synaptic current in CA3 pyramidal cells was used to measure kappa-2 receptor activation. GR89,696 had no effect on the perforant path-evoked dentate population spike; however, it did reverse the effects of the selective kappa-1 agonist U69,593 when co-perfused over the slices. In the CA3, GR89,696 inhibited the NMDA receptor-mediated synaptic current. The inhibition was antagonized by naloxone. The EC50 for GR89,696 on the NMDA current was 41.7 nM (95% CL, 7.0-248 nM). These findings indicate that GR89,696 is an agonist for kappa-2 opioid receptors and an antagonist at kappa-1 receptors in the guinea pig hippocampus.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 046144043

Download citation: RISBibTeXText

PMID: 9400009

Related references

Brief prenatal ethanol exposure alters behavioral sensitivity to the kappa opioid receptor agonist (U62,066E) and antagonist (Nor-BNI) and reduces kappa opioid receptor expression. Alcoholism Clinical and Experimental Research 38(6): 1630-1638, 2014

Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity. Synapse 34(4): 256-265, 1999

A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, natrindole: 5'-[N2-alkylamidino)methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists. Journal of Medicinal Chemistry 36(1): 179-180, 1993

Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. Journal of Medicinal Chemistry 44(13): 2073-2079, 2001

Differential time course of effects of kappa-opioid agonist treatment on dynorphin A levels and kappa-opioid receptor density. Journal of Molecular Neuroscience 24(2): 307-314, 2004

Effect of chronic administration of naltrexone on brain mu- and kappa-opioid receptors and responses to U-50,488H, a kappa-opioid receptor agonist in the mouse. FASEB Journal 9(3): A102, 1995

Analysis of the antinociceptive actions of the kappa-opioid agonist enadoline (CI-977) in neonatal and adult rats: comparison to kappa-opioid receptor mRNA ontogeny. Drug and Alcohol Dependence 38(3): 261-269, 1995

The mu-opioid activity of kappa-opioid receptor agonist compounds in the guinea pig ileum. European Journal of Pharmacology 212(2-3): 283-286, 1992

Differential effects of micro-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice. Behavioural Pharmacology 17(8): 691-701, 2006

The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue. Journal of Pharmacology and Experimental Therapeutics 311(2): 652-658, 2004

Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys. Psychopharmacology 176(2): 204-213, 2004

Effect of the kappa - opioid receptor agonist, U - 69593, on kappa receptor immunoreactivity in the nucleus accumbens of cocaine treated female rats. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 321 16, 2003

The stereoselective kappa-opioid receptor antagonist Mr 2266 does not exhibit stereoselectivity as an antagonist at the orphan opioid (ORL1) receptor. Naunyn-Schmiedeberg's Archives of Pharmacology 359(1): 17-20, 1999

Activation of c-fos mRNA in the brain by the kappa-opioid receptor agonist enadoline and the NMDA receptor antagonist dizocilpine. European Journal of Pharmacology 328(1): 31-36, 1997

Opioid receptor independent inhibition of Ca-2+ and K+ currents in NG108-15 cells by the kappa opioid receptor agonist U504488H. Neuroreport 7(11): 1809-1812, 1996